Puneeth Iyengar on Nutrition and Hydration for Patients with Lung Cancer.

Video

Dr. Puneeth Iyengar expresses the importance of nutrition and hydration for patients with stage III lung cancer.

Puneeth Iyengar, MD, PhD, assistant professor of Radiation Oncology at UT Southwestern Medical Center, explains the importance of nutrition and hydration for patients with stage III lung cancer.

For patients with stage III lung cancer, Iyengar stresses adequate nutrition and caloric intake but, even moreso, hydration. If hydration isn’t maintained, a patient can become run down and the chance of constipation, which could be exacerbated by narcotics, is increased.

Related Videos
Related Content
FDA Approves First ALK Inhibitor for Adjuvant Therapy in Early-Stage NSCLC

FDA Approves First ALK Inhibitor for Adjuvant Therapy in Early-Stage NSCLC

April 18th 2024
Article

Alectinib was approved for the treatment of patients with ALK-positive non-small cell lung cancer after surgical resection.

The Vitals

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

November 15th 2023
Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit

Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit

April 12th 2024
Article

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Adagrasib Provides Greater Benefit vs Docetaxel in KRAS G12C–Mutant NSCLC

Adagrasib Provides Greater Benefit vs Docetaxel in KRAS G12C–Mutant NSCLC

April 9th 2024
Article

Compared with docetaxel, adagrasib improved progression-free survival and objective response rate in patients with pretreated KRAS G12C–mutant non–small cell lung cancer.

TTFields Improves Time to Progression in Brain Metastases From NSCLC

TTFields Improves Time to Progression in Brain Metastases From NSCLC

April 8th 2024
Article

Tumor-treating fields significantly improved the time to intracranial progression in patients from the phase 3 METIS trial with brain metastases from non-small cell lung cancer.

© 2024 MJH Life Sciences

All rights reserved.